Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Cox, A. Rubin, M. Laviolette, I. Pavord, N. Thomson (Hamilton, Quebec, Canada; Porto Alegre, Brazil; Leicester, Glasgow, United Kingdom). Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial. Eur Respir J 2009; 34: Suppl. 53, 3044

Member's Comments

No comment yet.

Related content which might interest you: Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthma Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007 Clinical response of severe asthma patients following Bronchial Thermoplasty. Source: International Congress 2017 – To freeze or heat? Year: 2017 Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Safety of bronchial thermoplasty (bt), a novel procedure for severe asthma; positive safety profile in the air2 trial Source: Annual Congress 2009 - Treatment beyond inhalers Year: 2009 Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Towards optimal patient selection for bronchial thermoplasty treatment in severe asthma: results from the TASMA randomized trial Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Inhaled corticosteroids in patients with mild to moderate COPD with and without airway hyperresponsiveness to mannitol: A randomized placebo controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Efficacy of symbicort administration in patients with bronchial asthma Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008